Abemaciclib Neurofarmacocinética del glioma difuso de línea media mediante microdiálisis intratumoral
Factibilidad de evaluar la neurofarmacocinética de abemaciclib en gliomas difusos de línea media mediante microdiálisis intratumoral
Background:
Diffuse midline gliomas are the most aggressive brain tumors of childhood and young adults. Most people with these tumors survive less than 2 years. Researchers want to see if an anticancer drug (abemaciclib) can help.
Objective:
To see if researchers can measure how much abemaciclib is in a person's brain tumor and brain fluid after they take the drug for a few days.
Eligibility:
People aged 18 to 39 with recurrent high-grade glioma or diffuse midline glioma.
Design:
Participants will be screened with:
Medical history
Physical exam
Blood and urine tests
Tests of heart function
Imaging scans of the brain, with a contrast agent
Screening tests will be repeated during the study. Participants will also have chest X-rays.
Participants will take abemaciclib by mouth twice a day for 4 and a half days.
Participants will undergo surgery. They will have either a tumor biopsy (a needle will be inserted to remove a small piece of tissue) or a surgical resection (part or all of the tumor will be removed). A small tube (catheter) will be placed in their brain for 48 hours to collect fluid samples. They will have a neurological exam every few hours while the tube is in place. Two days later, the tube will be removed without surgery. Participants will stay in the hospital for about 4 days for treatment.
Based on the results of abemaciclib levels in the brain, participants may keep taking abemaciclib and another drug (temozolomide) by mouth until their cancer gets worse or they have bad side effects. While taking these two drugs, participants will come back to the clinic for follow-up routinely. They will be followed by the study for life....
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
- Droga: Pre-operative abemaciclib
- Dispositivo: Device for Cerebral Fluid Dialysate Collection
- Dispositivo: Ashion Analytics GEM ExTra
- Droga: abemaciclib + temozolomide
- Droga: Temozolomide
- Prueba de diagnóstico: Brain MRI
- Prueba de diagnóstico: Brain CT
- Prueba de diagnóstico: EKG
- Prueba de diagnóstico: Chest X-ray
- Procedimiento: Biopsy/resection
Descripción detallada
Background
Diffuse midline gliomas are the most aggressive brain tumors of childhood and young adults, with documented 2-year survival rates of <10%. These tumors are infiltrative midline high-grade gliomas. Treatment failure is due in part to the presence of the blood-brain barrier (BBB), which limits permeability of varied agents.
Efforts to evaluate drug delivery across the BBB in midline gliomas have been restricted to post biopsy specimens. In comparison, intracerebral microdialysis sampling of cortical tissue has been shown to be a highly effective tool in determining cortical neuropharmacokinetics (brain extracellular fluid penetration, accumulation and excretion) intratumorally and peritumorally in adult brain tumor participants. Microdialysis is underutilized in the adult brain tumor setting to evaluate chemotherapy or targeted therapy permeability.
Within the United States (US), midline gliomas are not routinely biopsied. However, in the last several years, using modern surgical techniques, biopsy at the time of diagnosis has been performed with acceptable risks (4% mortality rate), with a feasible means to molecularly characterize the tumors; in order to identify potentially druggable targets.
One of the main attributes of disease progression/proliferation in midline gliomas is associated with dysregulation of the cell cycle. Cyclin-dependent kinase inhibitor 2A (CDKN2A) is the primary inhibitory brake on cyclin-dependent kinase 4 and 6 (CDK4/6) driven signaling and is commonly deleted in glioblastoma, pancreas, bladder, breast and prostate cancer. The specific CDK4/6 inhibitor, abemaciclib, has Food and Drug Administration (FDA) approval for the treatment of metastatic breast cancer.
This is a safety and feasibility study to evaluate pharmacokinetic and pharmacodynamic effects post abemaciclib administration in recurrent high grade glioma participants (cortical and midline tumors). We propose a trial using clinical microdialysis, placed in diffuse midline glioma tissue post biopsy, as an experimental research tool, to assess central nervous system (CNS) drug entry and targeted inhibition with abemaciclib. These studies are focused with the overall intent to inform future clinical therapies and preclinical modeling.
Objectives:
To evaluate safety and feasibility of intratumoral microdialysis placement post high grade glioma resection or midline glioma biopsy
To evaluate safety and feasibility of brain interstitial dialysate sampling in glioma participants post abemaciclib administration
To measure intratumoral vs. systemic concentrations of abemaciclib in glioma participants post abemaciclib administration
Eligibility:
Participants must have recurrent high-grade glioma or diffuse midline glioma based on clinical and/or radiologic findings
Participants with cortical high-grade gliomas must have previous intra-operative pathology confirming disease
Participants must be =>18 and <= 39 years of age, at time of enrollment
Ability to swallow tablets/pills
Must have adequate organ function as per laboratory testing parameters
Abemaciclib administration must be able to begin no later than 14 days after the date of radiographic diagnosis (by T2 or fluid-attenuated inversion recovery (FLAIR) imaging)
Design:
This is a safety and feasibility study to evaluate tumor pharmacokinetics (PK) and pharmacodynamics (PD) of abemaciclib in recurrent high-grade glioma and midline glioma participants in need of surgical resection or biopsy, respectively.
All participants will take abemaciclib pre-operatively for 4.5 days (9 total doses of abemaciclib) at twice daily dosing.
A maximally safe surgical resection for cortical high-grade glioma or stereotactic needle biopsy for midline glioma will be performed in the operating room (OR). Microdialysis insertion (based on participant safety and surgical feasibility) will be performed post-biopsy in the OR and placement will be verified by brain computed tomography (CT).
Continuous microdialysis sampling will be obtained over the course of the next 48 hours, with subsequent removal of the catheter at the bedside.
After discharge from National Institutes of Health (NIH) inpatient, PK and PD findings will assist in determination of whether the participant will continue to receive abemaciclib therapy. If intratumoral or PK brain dialysate sampling concentrations are >10nmol/L, or PD findings suggest cyclin-dependent kinase (CDK) inhibition (decreased expression of Retinoblastoma protein (Rb) and/or topoisomerase II (topoII), then restart of abemaciclib therapy along with temozolomide will be administered for maintenance therapy post resection or biopsy.
Maintenance therapy will be abemaciclib 150mg po twice a day (BID) x 28 days together with temozolomide 200mg/m^2 po daily x 5 days in 28-day cycles (temozolomide 150mg/m^2 po daily x 5 days for cycle 1). After every 3 cycles, repeat brain magnetic resonance imaging's (MRIs) will be obtained to evaluate treatment response and disease progression.
If a participant starts to exhibit signs of clinical deterioration or radiographic progression, the participant will discontinue maintenance therapy, with ongoing contact for survival approximately every 6 months (+/- 14 days) until death.
Results of the PK measurements and molecular testing will be provided to the participant's home oncologist to provide for assistance with directed therapy decisions (outside of this investigational trial).
We propose to evaluate 5 participants. The accrual ceiling will be set at 17 participants to account for screen failures and inevaluable participants.
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Fase
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Maryland
-
Bethesda, Maryland, Estados Unidos, 20892
- National Institutes of Health Clinical Center
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
-
INCLUSION CRITERIA:
- Participants must have recurrent high-grade glioma or midline glioma based on clinical and/or radiologic findings
- Participants with cortical high-grade gliomas must have previous intra-operative pathology confirming disease
- Participants must be >= 18 and <= 39 years old at the time of enrollment
- Ability to swallow tablets/pills
Prior Therapies:
- At least 4 weeks must have elapsed since any major surgeries, with no evidence of infections. Minimally invasive biopsies (outside of the brainstem) and central line placements are not considered major surgeries
- Participants who have received prior treatment with abemaciclib or another specific cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor are not eligible for enrollment (ex., Ribociclib, Palbociclib - list is not all inclusive)
- Participants who received chemotherapy must have recovered (Common Terminology Criteria for Adverse Events [CTCAE] Grade <=1) from the acute effects of chemotherapy except for residual alopecia or Grade 2 peripheral neuropathy prior to treatment. A washout period of at least 14 days or 4 half-lives from last disease directed therapy, whichever is shorter, is required between last chemotherapy dose and treatment.
- Participants who received radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and treatment.
- Adequate performance scale as defined below:
- Karnofsky >=50% within 14 days prior to enrollment.
- Adequate organ function within 14 days prior to enrollment as defined below:
Hematologic Function: Participants must have an absolute neutrophil count >=1500/microliters, hemoglobin >=9 g/dL (transfusion independent, defined as not receiving blood transfusion unless related to trauma or surgeries), and platelets >=100,000/microliters (transfusion independent, defined as not receiving platelet transfusions unless related to trauma or surgeries)
Hepatic Function: Participants must have bilirubin within 1.5 x the upper limit of normal for age, with the exception of those with Gilbert syndrome, and aspartate aminotransferase (AST)/alanine aminotransferase (ALT) within < 3 x upper limit of normal.
Renal Function: Participants must have a creatinine clearance or radioisotope glomerular filtration rate (GFR) >60ml/min/1.73 m^2 or a normal serum creatinine.
Cardiac Function: Normal ejection fraction (echocardiogram (ECHO) or cardiac magnetic resonance imaging (MRI) >= 53% (or the institutional normal); Corrected QT (QTC) or Fridericia's corrected QT (QTcF) < 450 msec.
-
Willingness to avoid grapefruit or grapefruit juice during abemaciclib administration
-
Informed Consent: Ability of participant or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document.
-
Willingness of participant or LAR to sign a written informed consent document and co-enroll in study 03-N-0164
-
The effects of abemaciclib on the developing human fetus are unknown, however cyclin-dependent kinase (CDK)-inhibiting agents are known to be teratogenic. Temozolomide is a cytotoxic chemotherapeutic agent which is known to be teratogenic. For these reasons, women of child-bearing potential must agree to use a highly effective method of contraception prior to study entry, for the duration of study participation, and for 3 weeks after the last dose of abemaciclib and 6 months after temozolomide. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation.
- A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (>= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus).
- Woman participants of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 7 days of the first dose of abemaciclib.
Highly effective contraception includes intrauterine devices (IUD), hormonal (birth control pills, injections, implants), tubal ligation, or partners vasectomy.
--Cases of pregnancy that occur during maternal exposures to abemaciclib should be reported. If a participant or spouse/partner is determined to be pregnant following abemaciclib initiation she must discontinue treatment immediately. Data on fetal outcomes and breastfeeding are to be collected for regulatory reporting and drug safety evaluation.
-Abemaciclib administration must be able to begin no later than 14 days after the date of radiographic diagnosis (by T2 or FLAIR imaging)
EXCLUSION CRITERIA:
- Participants who cannot safely undergo a biopsy due to contraindications
- Pregnant women, or women who intent to become pregnant during the study, are excluded from this study because of the teratogenic effects of abemaciclib. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with these agents, breastfeeding should be discontinued if the mother is treated on study.
- Serious preexisting medical condition(s) that would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest requiring oxygen therapy, severe renal impairment [e.g. estimated creatinine clearance <30ml/min], history of major surgical resection involving the stomach or small bowel that would preclude adequate absorption, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea).
- Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, active bleeding diatheses or renal transplant, or psychiatric illness/social situations that would limit compliance with study requirements.
- Personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest.
- Active systemic bacterial infection (requiring intravenous [IV] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C [for example, hepatitis B surface antigen positive]. Participants with HIV who have adequate cluster of differentiation 4 (CD4) counts and who have no requirement for antiviral therapy will be eligible. NOTE: Screening is not required for enrollment.
- Requires treatment with strong/moderate cytochrome P450, family 3, subfamily A. (CYP3A) inhibitors or inducers. Participants receiving any medications or substances that are inducers or strong/moderate inhibitors of CYP3A4 are ineligible. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently updated medical reference. As part of the enrollment/informed consent procedures, the participant will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the participant is considering a new over-the-counter medicine or herbal product.
- Inability to undergo MRI and/or contraindication for MRI examinations following the MRI protocol (see Study Procedure Manual). Prosthesis or orthopedic or dental braces that would interfere with MRI.
- Refractory nausea and vomiting that would limit drug administration in the opinion of the Principal Investigator
- Known severe hypersensitivity to abemaciclib, temozolomide or any excipient of abemaciclib or temozolomide or history of allergic reactions attributed to compounds of similar chemical or biologic composition to abemaciclib and temozolomide.
- Clinical judgment by the investigator that the participant should not participate in the study
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Arm 1/Cohort 1/ Abemaciclib and Microdialysis Monitoring
Abemaciclib orally twice a day (BID) for 4.5 days followed by resection or biopsy and microdialysis catheter placement with continuous monitoring for 48 hours post-operative and genomic sampling of tissue/blood; followed by Arm 2/abemaciclib + temozolomide maintenance therapy. |
Pre-operatively for 4.5 days; 200mg twice daily (9 total doses)
Otros nombres:
Post-resection or post-biopsy continuous intracerebral microdialysis sampling for 48 hours to assess central nervous system (CNS) drug entry and targeted inhibition with abemaciclib Resection/biopsy genomic sampling of tumor tissue and blood to identify therapeutic targets
Otros nombres:
Abemaciclib 150mg by mouth (po) twice a day (BID) and temozolomide 200mg/m^2 po daily x 5 days in 28-day cycles (temozolomide 150mg/m^2 po daily x 5 days for cycle 1)
Otros nombres:
Temozolomide 150mg/m^2 by mouth (po) daily x 5 days for cycle 1
Otros nombres:
Screening (within 14 days prior to enrollment), baseline (within 14 days of first dose), as clinically indicated at catheter removal Day 7 (>48 hours post op), maintenance therapy (after every 3 cycles), and post treatment (safety and long-term follow-up) as clinically indicated.
Otros nombres:
Microdialysis (catheter in place) Day 5 and Day 6, and as clinically indicated at catheter removal Day 7 (>48 hours post op).
Otros nombres:
Screening (within 14 days prior to enrollment), baseline (within 14 days of first dose), and as clinically indicated at catheter removal Day 7 (>48 hours post op).
Otros nombres:
Baseline (within 14 days of first dose), and as clinically indicated at catheter removal Day 7 (>48 hours post op).
Otros nombres:
Microdialysis (catheter in place) Day 5 and Day 6.
Otros nombres:
|
|
Experimental: Arm 2/Cohort 2/Abemaciclib + Temozolomide Maintenance Therapy
Maintenance therapy is abemaciclib 150mg by mouth (PO) BID x 28 days + temozolomide 200mg/m^2 PO daily x 5 days in 28-day cycles (temozolomide 150mg/m^2 PO daily x 5 days for cycle 1). |
Pre-operatively for 4.5 days; 200mg twice daily (9 total doses)
Otros nombres:
Post-resection or post-biopsy continuous intracerebral microdialysis sampling for 48 hours to assess central nervous system (CNS) drug entry and targeted inhibition with abemaciclib Resection/biopsy genomic sampling of tumor tissue and blood to identify therapeutic targets
Otros nombres:
Abemaciclib 150mg by mouth (po) twice a day (BID) and temozolomide 200mg/m^2 po daily x 5 days in 28-day cycles (temozolomide 150mg/m^2 po daily x 5 days for cycle 1)
Otros nombres:
Temozolomide 150mg/m^2 by mouth (po) daily x 5 days for cycle 1
Otros nombres:
Screening (within 14 days prior to enrollment), baseline (within 14 days of first dose), as clinically indicated at catheter removal Day 7 (>48 hours post op), maintenance therapy (after every 3 cycles), and post treatment (safety and long-term follow-up) as clinically indicated.
Otros nombres:
Microdialysis (catheter in place) Day 5 and Day 6, and as clinically indicated at catheter removal Day 7 (>48 hours post op).
Otros nombres:
Screening (within 14 days prior to enrollment), baseline (within 14 days of first dose), and as clinically indicated at catheter removal Day 7 (>48 hours post op).
Otros nombres:
Baseline (within 14 days of first dose), and as clinically indicated at catheter removal Day 7 (>48 hours post op).
Otros nombres:
Microdialysis (catheter in place) Day 5 and Day 6.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Percentage of Participants Who Have Adequate Intra-tumoral Sampling Reported With an 80% Confidence Interval
Periodo de tiempo: At surgery (less than 14 hours from surgery), biopsy (after 4 days of abemaciclib), and 2, 6, 10, 14, 18, 22, 26, 30, 34, 38,40, 44, and 48 hours post catheter insertion
|
The percentage of participants who have adequate intra-tumoral sampling was determined and reported with an 80% confidence interval. Adequate intra-tumoral tissue concentration is <10nmol/L. Intra-tumoral sampling was performed by microdialysis. |
At surgery (less than 14 hours from surgery), biopsy (after 4 days of abemaciclib), and 2, 6, 10, 14, 18, 22, 26, 30, 34, 38,40, 44, and 48 hours post catheter insertion
|
|
Percentage of Participants Who Have Adequate Intra-tumoral Sampling Reported With a 95% Confidence Interval
Periodo de tiempo: At surgery (less than 14 hours from surgery), biopsy (after 4 days of abemaciclib), and 2, 6, 10, 14, 18, 22, 26, 30, 34, 38,40, 44, and 48 hours post catheter insertion
|
The percentage of participants who have adequate intra-tumoral sampling was determined and reported with a 95% confidence interval. Adequate intra-tumoral tissue concentration is <10nmol/L. Intra-tumoral sampling was performed by microdialysis. |
At surgery (less than 14 hours from surgery), biopsy (after 4 days of abemaciclib), and 2, 6, 10, 14, 18, 22, 26, 30, 34, 38,40, 44, and 48 hours post catheter insertion
|
|
Number of Participants Who Experience Any Type Grade 1, 2, 3, 4, and/or 5 Adverse Event (AE)/Complication Possibly, Probably, and/or Definitely Related to Adverse Events for Participants (pt) Receiving Abemaciclib
Periodo de tiempo: Study Day 1 through 30 days after the last intervention through study completion, an average of 4.5 months
|
AEs were assessed by the Common Terminology Criteria for Adverse Events v5.0. A non-serious AE is any untoward medical occurrence. A serious AE is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the pt or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 1:mild. Grade 2: moderate. Grade 3: severe. Grade 4: life-threatening. Grade 5: death related to adverse event. All participants who receive at least 1 dose of abemaciclib or undergo the procedure to place the catheter will have their safety information reported. This table is related to AEs from abemaciclib therapy(pre-surgery). Values in the table will and should be different than other AE tables based on toleration of therapy at varied times for each pt. |
Study Day 1 through 30 days after the last intervention through study completion, an average of 4.5 months
|
|
Number of Grade 1, 2, 3, 4, and/or 5 Adverse Events (AE) At Least Possibly Related Adverse Events for Participants(pt) Receiving Combination Therapy With Abemaciclib and Temozolomide
Periodo de tiempo: Study Day 1 through 30 days after the last intervention through study completion, an average of 4.5 months
|
AEs were assessed by the Common Terminology Criteria for AEs (CTCAE v5.0). A non-serious AE is any untoward medical occurrence. A serious AE is an adverse event or suspected adverse reaction that results in death, life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 1: mild. Grade 2: moderate. Grade 3: severe. Grade: 4 life-threatening. Grade 5: death related to AE. All participants who receive at least 1 dose of abemaciclib or undergo the procedure to place the catheter are reported. This table is related to AEs from abemaciclib post-surgery,given during maintenance cycle with temozolomide. Values in the table will and should be different than other AE tables based on toleration of therapy at varied times for each pt. |
Study Day 1 through 30 days after the last intervention through study completion, an average of 4.5 months
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Time to Maximum Observed Plasma Concentration an Hour (Tmax(hr) of Drug Abemaciclib
Periodo de tiempo: Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
|
Blood samples were collected to determine the time to maximum observed plasma concentration an hour (Tmax(hr) of drug abemaciclib. Abemaciclib levels in plasma were measured by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) analysis. |
Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
|
|
Maximum Plasma Concentration (Cmax) of Drug Abemaciclib
Periodo de tiempo: Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
|
Blood samples were collected to determine the maximum plasma concentration of drug abemaciclib. Abemaciclib levels in plasma were measured by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) analysis. |
Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
|
|
Area Under the Plasma Concentration (AUC) of Drug Abemaciclib
Periodo de tiempo: Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
|
AUC is a measure of the drug plasma serum concentration of abemaciclib over time. It is used to characterize drug absorption. Abemaciclib levels in plasma were measured by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) analysis. |
Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
|
|
Maximum Plasma Concentration (Cmax) of Unbound Abemaciclib
Periodo de tiempo: Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
|
Unbound abemaciclib plasma exposure was calculated by the total drug exposure multiplied by the mean unbound fraction (fu,0.06) in human plasma. |
Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
|
|
Area Under the Plasma Concentration (AUC) of Unbound Abemaciclib
Periodo de tiempo: Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
|
AUC is a measure of the total drug plasma serum concentration of abemaciclib over time. It is used to characterize drug absorption. Unbound abemaciclib plasma exposure was calculated by the total drug exposure multiplied by the mean unbound fraction (fu,0.06) in human plasma. |
Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
|
|
Time to Maximum Observed Plasma Concentration an Hour (Tmax(hr) of Brain Dialysate
Periodo de tiempo: Approximately 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 40, 44, and 48 hours post catheter insertion
|
Urea concentrations in blood and brain interstitial fluid were measured at timed intervals. Abemaciclib levels in plasma, brain tissue and dialysate were measured and compared by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) analysis to determine plasma concentration. |
Approximately 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 40, 44, and 48 hours post catheter insertion
|
|
Maximum Plasma Concentration (Cmax) of Brain Dialysate
Periodo de tiempo: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 40, 44, and 48 hours post catheter insertion
|
Blood and brain interstitial fluid were obtained via microdialysis catheter in the brain and urea (metabolite) concentrations in blood and brain interstitial fluid were measured at timed intervals. Abemaciclib levels in plasma, brain tissue and dialysate were measured by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) to determine plasma concentration of drug in the brain. |
2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 40, 44, and 48 hours post catheter insertion
|
|
Area Under the Plasma Concentration (AUC) of Brain Dialysate
Periodo de tiempo: Approximately 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 40, 44, and 48 hours post catheter insertion
|
AUC is a measure of the total drug plasma serum concentration of abemaciclib over time. Blood and brain interstitial fluid were obtained via microdialysis catheter in the brain and urea (metabolite) concentrations in blood and brain interstitial fluid were measured at timed intervals. Abemaciclib levels in plasma, brain tissue and dialysate were measured by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) analysis to determine concentration of drug in the brain. |
Approximately 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 40, 44, and 48 hours post catheter insertion
|
|
Concentration of Total Drug Abemaciclib From Tissue Obtained Via Brain Biopsy
Periodo de tiempo: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 40, 44, and 48 hours post catheter insertion
|
Biopsied tumor tissue was obtained using a stereotactic needle in the brain. A minimum of 6 samples were taken and analyzed by liquid chromatography tandem mass spectrometry (LC/MS/MS) to determine drug concentrations in the brain tissue. |
2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 40, 44, and 48 hours post catheter insertion
|
|
Brain Biopsy Sampling Time
Periodo de tiempo: 2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 40, 44, and 48 hours post catheter insertion
|
Brain biopsy sampling time is the timing of when the tumor tissue was biopsied since the last dose of abemaciclib. |
2, 6, 10, 14, 18, 22, 26, 30, 34, 38, 40, 44, and 48 hours post catheter insertion
|
|
Ratio of Area Under the Plasma Concentration (AUC) in Brain Dialysate to Unbound Drug Abemaciclib AUC in Plasma
Periodo de tiempo: Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
|
AUC is a measure of the total drug plasma serum concentration of abemaciclib over time. Unbound abemaciclib plasma exposure was calculated by the total drug exposure multiplied by the mean unbound fraction (fu,0.06) in human plasma. Abemaciclib levels in plasma, brain tissue and dialysate were measured by Liquid Chromatography with Tandem Mass Spectrometry (LC-MS/MS) analysis. |
Approximately 5, 6, 10, 12, 14, 28, 52, 76 hours after last dose of abemaciclib
|
Otras medidas de resultado
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0)
Periodo de tiempo: From the first study intervention, Study Day 1 through 30 days after the last abemaciclib administration, a range of every 28 ± 3 days, up to an average of 5 months.
|
Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. |
From the first study intervention, Study Day 1 through 30 days after the last abemaciclib administration, a range of every 28 ± 3 days, up to an average of 5 months.
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Sadhana Jackson, M.D., National Cancer Institute (NCI)
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Actual)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades Cerebrales
- Enfermedades del Sistema Nervioso Central
- Enfermedades del Sistema Nervioso
- Neoplasias por sitio
- Neoplasias
- Neoplasias por tipo histológico
- Neoplasias Glandulares y Epiteliales
- Neoplasias Neuroepiteliales
- Tumores neuroectodérmicos
- Neoplasias De Células Germinales Y Embrionarias
- Neoplasias De Tejido Nervioso
- Neoplasias del Sistema Nervioso
- Neoplasias del Sistema Nervioso Central
- Glioma
- Neoplasias Cerebrales
- Químicos orgánicos
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Técnicas de investigación
- Manejo de muestras
- Técnicas de laboratorio clínico
- Técnicas y procedimientos de diagnóstico
- Diagnóstico
- Procedimientos quirúrgicos, operativo
- Azoles
- Técnicas citológicas
- Citodiagnóstico
- Dacarbazina
- Triazenes
- Imidazoles
- Técnicas de diagnóstico, quirúrgico
- Técnicas de diagnóstico, cardiovascular
- Pruebas de funciones cardíacas
- Electrodiagnóstico
- Temozolomida
- Biopsia
- abemaciclib
- Electrocardiografía
- Imágenes de diagnóstico
Otros números de identificación del estudio
Otros números de identificación del estudio
- 220003
- 22-C-0003
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
All individual participant data (IPD) recorded in the medical record will be shared with intramural investigators upon request. In addition, all large-scale genomic sequencing data will be shared with subscribers to the database of Genotypes and Phenotypes (dbGaP).
Marco de tiempo para compartir IPD
Clinical data available during the study and indefinitely. Genomic data will be shared from the time of upload to the database of Genotypes and Phenotypes (dbGaP).
Criterios de acceso compartido de IPD
Clinical data will be made available via subscription to Biomedical Translational Research Information System (BTRIS) and with the permission of the study principal investigator (PI). Requests for all collected IPD data from clinical trials, conducted under a binding collaborative agreement between National Cancer Institute (NCI)/Division of Cancer Treatment and Diagnosis (DCTD) and a pharmaceutical/biotechnology company, that are not under Data and Safety Monitoring Board (DSMB) monitoring must be in compliance with the terms of the binding collaborative agreement and must be approved by NCI/DCTD and the Pharmaceutical Collaborator (i.e., the NCI Experimental Therapeutics Clinical Trials Network (ETCTN) Director in conjunction with the NCI/DCTD Regulatory Affairs Branch). Genomic individual participant data (IPD) will be shared through the database of Genotypes and Phenotypes (dbGaP) per rules of the database, for purposes of genomic analysis.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
- CIF
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .